Want to see JP:4544 full AI Analyst Report?
Top Page
HUGroup Holdings
(4544)
Select Model
Select Model
Rating:68Neutral
Price Target:
¥3,959.00
▲(14.03% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by improving financial performance (revenue and profit recovery with solid free cash flow) but held back by still-subdued margins and ROE versus prior peak years. Technicals add support as the stock is above major moving averages with positive momentum, while valuation is balanced with a mid-range P/E and a meaningful dividend yield.
Positive Factors
Revenue and profit recovery
Strong top-line acceleration and a return to positive earnings indicate renewed demand for diagnostic services and improved operating execution. If sustained, this recovery can rebuild the earnings base over the next several quarters, though normalization is not complete.
Negative Factors
Subdued net margins
Although earnings have recovered, profitability remains far below prior peak levels. Persistently thin margins leave less room to absorb wage, logistics, technology, or testing-cost pressure and imply that the current recovery has not yet restored historical earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and profit recovery
Strong top-line acceleration and a return to positive earnings indicate renewed demand for diagnostic services and improved operating execution. If sustained, this recovery can rebuild the earnings base over the next several quarters, though normalization is not complete.
Read all positive factors
HUGroup Holdings (4544) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥208.95B
Dividend Yield3.43%
Average Volume (3M)243.85K
Price to Earnings (P/E)21.1
Beta (1Y)0.28
Revenue Growth1.47%
EPS Growth605.26%
CountryJP
Employees5,157
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)172.55
Shares Outstanding57,494,423
10 Day Avg. Volume223,460
30 Day Avg. Volume243,853
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.30
Price to Sales (P/S)0.72
P/FCF Ratio9.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)98.95
Revenue Forecast (FY)¥256.95B
HUGroup Holdings Business Overview & Revenue Model
Company Description
Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries acr...
How the Company Makes Money
HUGroup Holdings makes money primarily through fees charged for diagnostic-related services delivered by its subsidiaries, especially clinical laboratory testing performed for external medical providers. Key revenue streams generally include (1) r...
HUGroup Holdings Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
63
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 248.56B | 247.36B | 243.03B | 236.95B | 260.91B | 272.94B |
| Gross Profit | 71.87B | 70.77B | 67.20B | 63.23B | 89.92B | 111.80B |
| EBITDA | 33.54B | 31.02B | 24.55B | 13.65B | 42.97B | 56.34B |
| Net Income | 9.59B | 6.82B | 2.76B | -7.55B | 15.68B | 29.60B |
Balance Sheet | ||||||
| Total Assets | 263.00B | 267.47B | 279.58B | 295.36B | 301.76B | 288.60B |
| Cash, Cash Equivalents and Short-Term Investments | 44.51B | 48.10B | 40.88B | 39.95B | 44.19B | 46.49B |
| Total Debt | 60.27B | 74.33B | 86.65B | 81.94B | 77.16B | 73.00B |
| Total Liabilities | 128.36B | 129.99B | 142.28B | 152.85B | 151.71B | 148.41B |
| Stockholders Equity | 134.61B | 137.41B | 137.12B | 142.50B | 150.05B | 140.18B |
Cash Flow | ||||||
| Free Cash Flow | 21.19B | 19.21B | 20.88B | 4.18B | 18.30B | 31.50B |
| Operating Cash Flow | 23.93B | 21.57B | 24.96B | 16.55B | 32.53B | 55.23B |
| Investing Cash Flow | 11.47B | 11.34B | -18.96B | -16.05B | -29.58B | -30.86B |
| Financing Cash Flow | -27.69B | -26.39B | -5.30B | -5.78B | -5.76B | -21.73B |
HUGroup Holdings Technical Analysis
Positive
3472.00
Price Trends
3406.86
Positive
3306.20
Positive
3307.43
Positive
Market Momentum
76.82
Negative
60.53
Neutral
81.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4544, the sentiment is Positive. The current price of 3472 is below the 20-day moving average (MA) of 3541.85, above the 50-day MA of 3406.86, and above the 200-day MA of 3307.43, indicating a bullish trend. The MACD of 76.82 indicates Negative momentum. The RSI at 60.53 is Neutral, neither overbought nor oversold. The STOCH value of 81.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4544.
HUGroup Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥215.89B | 12.93 | ― | 2.35% | 8.76% | 8.19% | |
68 Neutral | ¥208.95B | 21.10 | 2.65% | 3.60% | 1.47% | 605.26% | |
67 Neutral | ¥207.09B | 16.11 | 9.09% | 2.32% | 6.54% | -2.44% | |
65 Neutral | ¥111.59B | 14.22 | ― | 0.34% | 9.89% | 11.20% | |
59 Neutral | ¥88.52B | 44.69 | 6.35% | ― | 24.03% | 34.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4544
HUGroup Holdings
3,641.00
104.89
2.97%
JP:3360
Ship Healthcare Holdings
2,346.50
175.68
8.09%
JP:4480
Medley
2,687.00
203.00
8.17%
JP:3148
Create SD Holdings Co., Ltd.
3,400.00
53.57
1.60%
JP:9267
Genky DrugStores Co., Ltd.
3,675.00
-895.43
-19.59%
HUGroup Holdings Corporate Events
H.U. Group Holdings Posts Strong Profit Rebound and Maintains Dividend Guidance
Aug 12, 2026
H.U. Group Holdings reported consolidated net sales of ¥62.59 billion for the three months ended June 30, 2026, up 1.9% year on year, with operating profit surging 141.1% to ¥2.10 billion and profit attributable to owners of parent rebou...
H.U. Group Advances Share Buyback Under ¥5 Billion Program
Aug 3, 2026
H.U. Group Holdings has disclosed the latest progress of its share buyback program authorized by its board in May 2026, conducted under provisions of the Companies Act. The company is purchasing its own common shares on the Tokyo Stock Exchange, s...
H.U. Group Reports Progress on ¥5 Billion Share Buyback Program
Jul 1, 2026
H.U. Group Holdings has reported progress on its ongoing share buyback program, authorized by its board in mid May under provisions of the Companies Act. Between June 1 and June 30, the company repurchased 378,300 common shares on the Tokyo Stock ...
H.U. Group Begins ¥5 Billion Share Buyback With Initial Treasury Stock Repurchase
Jun 1, 2026
H.U. Group Holdings, Inc., a healthcare and clinical testing services provider listed on the Tokyo Stock Exchange Prime Market, continues to leverage its financial position to support shareholder-focused capital policies. The company operates acro...
H.U. Group to Revise Articles, Loosen Rules on Meeting Conveners
May 22, 2026
H.U. Group Holdings has approved a proposal to amend its Articles of Incorporation to give the Board of Directors greater flexibility over how shareholder meetings and board meetings are convened and chaired. The changes shift authority from the R...
H.U. Group Holdings Keeps Annual Dividend Unchanged at ¥125 Per Share
May 22, 2026
H.U. Group Holdings will maintain its shareholder return stance by paying a year-end dividend of 63 yen per share for the fiscal year ended March 31, 2026, matching both its prior forecast and the previous year’s payout. The total annual div...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.